 <h1>Methotrexate LPF Sodium Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>methotrexate</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about methotrexate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Methotrexate LPF Sodium.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to methotrexate: oral solution, oral tablet</i></p><p>Other dosage forms:</p><ul><li>powder for solution, solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Solution)</p><p>Severe Toxic Reactions, Including Embryo-Fetal ToxicityMethotrexate can cause severe or fatal toxicities. Monitor closely and modify dose or discontinue for the following toxicities: bone marrow suppression, infection, renal, gastrointestinal, hepatic, pulmonary, hypersensitivity and dermatologic.Methotrexate can cause embryo-fetal toxicity and fetal death. Use in polyarticular juvenile idiopathic arthritis is contraindicated in pregnancy. Consider the benefits and risks of methotrexate and risks to the fetus when prescribing methotrexate to a pregnant patient with a neoplastic disease. Advise patients to use effective contraception during and after treatment with methotrexate.</p><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Embryo-Fetal Toxicity Hypersensitivity Reactions, and Severe Adverse ReactionsMethotrexate tablets can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate tablets are contraindicated in pregnancy. For neoplastic diseases, advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.Methotrexate tablets are contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis.Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys. Withhold or discontinue methotrexate tablets as appropriate.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, methotrexate (the active ingredient contained in Methotrexate LPF Sodium) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking methotrexate:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>bloody vomit</li>
<li>diarrhea</li>
<li>increased heartbeat</li>
<li>itching, rash, reddening of the skin</li>
<li>joint pain</li>
<li>nausea</li>
<li>pinpoint red spots on the skin</li>
<li>sores in the mouth or lips</li>
<li>stomach pain</li>
<li>swelling of the eyelids, face, lips, hands, feet, or lower legs</li>
<li>swelling or inflammation of the mouth</li>
<li>trouble breathing</li>
<li>unusual bleeding or bruising</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>bloody nose</li>
<li>blurred vision</li>
<li>body and muscle pain</li>
<li>burning while urinating</li>
<li>confusion</li>
<li>continuing ringing, buzzing, or other unexplained noise in the ears</li>
<li>cough or hoarseness</li>
<li>cracked, dry, scaly skin</li>
<li>dark urine</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>ear congestion</li>
<li>fever or chills</li>
<li>headache</li>
<li>loss of appetite</li>
<li>loss of hearing</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>runny nose</li>
<li>seizures</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>unusual tiredness or weakness</li>
<li>weight loss</li>
<li>white or brownish vaginal discharge</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blurred or change in vision</li>
<li>changes in skin color</li>
<li>confusion</li>
<li>constipation</li>
<li>decreased interest in sexual intercourse</li>
<li>difficulty in moving</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>dry mouth</li>
<li>dryness or soreness of throat</li>
<li>eye pain</li>
<li>fruit-like breath odor</li>
<li>heartburn</li>
<li>inability to have or keep an erection</li>
<li>increased hunger or thirst</li>
<li>indigestion</li>
<li>irritation in the mouth</li>
<li>large, flat, blue, or purplish patches in the skin</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of consciousness</li>
<li>menstrual problem</li>
<li>night blindness</li>
<li>pain in the chest or groin</li>
<li>pain, redness, swelling, or tenderness in the arm or leg</li>
<li>red skin lesions, often with a purple center</li>
<li>red, wart-like spots on the skin</li>
<li>sudden loss of coordination</li>
<li>sudden onset of slurred speech</li>
<li>swelling or soreness of the breasts</li>
<li>swollen, painful, or tender lymph glands in the neck or armpit</li>
<li>tingling or numbness in the hands, feet, or lips</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of methotrexate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Hair loss or thinning</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>hard, red, swollen skin irritation</li>
<li>pimples</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to methotrexate: compounding powder, injectable powder for injection, injectable solution, intramuscular solution, oral solution, oral tablet, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Vasculitis</p>
<p><b>Rare</b> (less than 0.1%): Pericarditis, pericardial effusion, pericardial tamponade, hypotension, thromboembolic events (e.g., arterial thrombosis, cerebral thrombosis, thrombophlebitis, deep vein thrombosis, retinal vein thrombosis, pulmonary embolism), myocardial ischemia </p>
<p><b>Frequency not reported</b>: Cerebral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Exanthema, erythema, itching</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria, photosensitivity, depigmentation or hyperpigmentation of the skin, alopecia, increase of rheumatic nodules, painful lesions of psoriatic plaque, herpetiform eruption of the skin, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome)</p>
<p><b>Rare</b> (0.01% to 0.1%): Increased pigmentary changes of nails, acne, petechiae, ecchymoses, erythema multiforme, cutaneous erythematous eruptions </p>
<p><b>Very rare</b> (less than 0.01%): Furunculosis, telangiectasia</p>
<p><b>Frequency not reported</b>: Exfoliative dermatitis, skin necrosis, skin ulceration, folliculitis, hidradenitis, allergic vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Inflammation and ulceration of the vagina</p>
<p><b>Very rare</b> (less than 0.01%): Loss of libido (males and females), impotence, impaired menstruation, vaginal discharge, infertility, abortion, fetal death, fetal defects, gynecomastia, defective oogenesis or spermatogenesis, transient oligospermia, vaginal bleeding<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Anorexia, nausea, vomiting, abdominal pain, inflammation, ulcerations of the mucous membrane of mouth and throat (especially during the first 24 to 48 hours after administration), stomatitis, dyspepsia, dehydration</p>
<p><b>Common</b> (1% to 10%): Diarrhea (especially during the first 24 to 48 hours after administration)</p>
<p><b>Uncommon</b> (0.1% to 1%): GI bleeding and ulcers, pancreatitis</p>
<p><b>Rare</b> (0.01% to 0.1%): Gingivitis, enteritis, melena, malabsorption </p>
<p><b>Very rare</b> (less than 0.01%): Hematemesis, toxic megacolon</p>
<p><b>Frequency not reported</b>: Glossitis<sup>[Ref]</sup></p><h3>General</h3><p>Generally, the incidence and severity of acute side effects are related to dose and frequency of administration.  The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, abdominal distress, malaise, undue fatigue, chills and fever, dizziness, and decreased resistance to infection.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Dysuria</p>
<p><b>Rare</b> (0.01% to 0.1%): Oliguria, anuria, azotemia</p>
<p><b>Very rare</b> (less than 0.01%): Proteinuria</p>
<p><b>Frequency not reported</b>: Cystitis, hematuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukocytopenia, thrombocytopenia, anemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancytopenia, agranulocytosis, hematopoietic disorders</p>
<p><b>Rare</b> (0.01% to 0.1%): Megaloblastic anemia </p>
<p><b>Very rare</b> (less than 0.01%): Severe bone marrow depression, aplastic anemia, lymphadenopathy, lymphoproliferative disorders (partly reversible), eosinophilia, neutropenia </p>
<p><b>Frequency not reported</b>: Hemorrhage, hematoma, myelosuppression<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increase in liver related enzymes (ALAT, ASAT, alkaline phosphatase, bilirubin, and LDH levels) is commonly reported but usually resolves within one month after cessation of therapy</p>
<p><b>Uncommon</b> (0.1% to 1%): Development of liver fattening, fibrosis and cirrhosis (occurs frequently despite regularly monitored, normal values of liver enzymes), drop of serum albumin</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute hepatitis, hepatotoxicity </p>
<p><b>Very rare</b> (less than 0.01%): Reactivation of chronic hepatitis, acute liver degeneration, liver insufficiency, liver failure, liver atrophy, necrosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic vasculitis, severe allergic reactions progressing to anaphylactic shock<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Disseminated herpes zoster, pneumocystis carinii pneumonia</p>
<p><b>Very rare</b> (less than 0.01%): Immunosuppression, hypogammaglobulinemia, sepsis, opportunistic infections (may be fatal in some cases), infections caused by the cytomegalic virus, acute paronychia</p>
<p><b>Frequency not reported</b>: Nocardiosis, cryptococcus mycosis, disseminated herpes simplex, listeria meningitis, mycobacterium avium, intracellular pneumonia, systemic fungal infections (e.g., cryptococcosis, nocardiosis, aspergillosis, histoplasmosis), sepsis, decreased resistance to infection, pneumocystis jiroveci, pneumonia (most common infection), respiratory tract infection, cutaneous bacterial infections, pneumonia, reactivation of hepatitis B infection, worsening of hepatitis C infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Osteoporosis, arthralgia, myalgia</p>
<p><b>Rare</b> (0.01% to 0.1%): Stress fracture, nodulosis </p>
<p><b>Very rare</b> (less than 0.01%): Pain, muscular asthenia or paresthesia of the extremities</p>
<p><b>Frequency not reported</b>: Osteoporosis, osteonecrosis (aseptic necrosis of the femoral head), soft tissue necrosis, abnormal tissue cell changes, arthralgia/myalgia, back pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, drowsiness</p>
<p><b>Uncommon</b> (0.1% to 1%): Vertigo, confusion, seizures, convulsion, encephalopathy</p>
<p><b>Very rare</b> (less than 0.01%): Paresis, effect on speech including dysarthria and aphasia, myelopathy, changes in sense of taste (metallic taste), meningism, acute aseptic meningitis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Severely impaired vision, visual disturbances, blurred vision </p>
<p><b>Very rare</b> (less than 0.01%): Conjunctivitis, retinopathy, transient blindness/loss of vision, periorbital edema, blepharitis, epiphora, photophobia, eye discomfort<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Lymphomas and leukemias have been associated with this drug<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very rare</b> (less than 0.01%): Fever, impaired wound healing</p>
<p><b>Frequency not reported</b>: Fetal death, fetal damage, abortion, tinnitus, chills, malaise, fatigue<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Inflammation and ulceration of the urinary bladder (possibly with hematuria)</p>
<p><b>Rare</b> (0.01% to 0.1%): Renal failure, elevated serum creatinine and urea level </p>
<p><b>Frequency not reported</b>: Renal insufficiency (usually with high doses), severe nephropathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary complications due to interstitial alveolitis pneumonitis (e.g., general illness, dry/nonproductive cough, shortness of breath progressing to rest dyspnea, chest pain, fever)</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary fibrosis</p>
<p><b>Rare</b> (0.01% to 0.1%): Pharyngitis, apnea, bronchial asthma </p>
<p><b>Very rare</b> (less than 0.01%): Pneumocystis carinii pneumonia, chronic obstructive pulmonary disease, pleural effusion</p>
<p><b>Frequency not reported</b>: Acute pulmonary edema, pleurisy, hypoxia, respiratory failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (0.01% to 0.1%): Diabetes mellitus, hyperuricemia </p>
<p><b>Frequency not reported</b>: Metabolic disorder, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (0.01% to 0.1%): Mood alterations </p>
<p><b>Very rare</b> (less than 0.01%): Insomnia, cognitive dysfunction</p>
<p><b>Frequency not reported</b>: Psychosis, depression, confusion, irritability<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Methotrexate Sodium (methotrexate)." Teva Pharmaceuticals (formerly IVAX), Miami, FL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Does it cause weight gain?</li>
<li>How long does it take to work?</li>
<li>Why should I take folic acid with methotrexate?</li>
<li>How long does methotrexate stay in your system?</li>
<li>What are the different brands of methotrexate?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Methotrexate LPF Sodium (methotrexate)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: antimetabolites</li>
<li>FDA Alerts (5)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Rasuvo, Otrexup, Trexall, Rheumatrex Dose Pack, ... +2 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Acute Lymphocytic Leukemia</li>
<li>Breast Cancer</li>
<li>Choriocarcinoma</li>
<li data-more-config-id="list-data-resources-conditions">... +17 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to methotrexate: compounding powder, injectable powder for injection, injectable solution, intramuscular solution, oral solution, oral tablet, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Vasculitis</p><p><b>Rare</b> (less than 0.1%): Pericarditis, pericardial effusion, pericardial tamponade, hypotension, thromboembolic events (e.g., arterial thrombosis, cerebral thrombosis, thrombophlebitis, deep vein thrombosis, retinal vein thrombosis, pulmonary embolism), myocardial ischemia </p><p><b>Frequency not reported</b>: Cerebral edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Exanthema, erythema, itching</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, photosensitivity, depigmentation or hyperpigmentation of the skin, alopecia, increase of rheumatic nodules, painful lesions of psoriatic plaque, herpetiform eruption of the skin, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome)</p><p><b>Rare</b> (0.01% to 0.1%): Increased pigmentary changes of nails, acne, petechiae, ecchymoses, erythema multiforme, cutaneous erythematous eruptions </p><p><b>Very rare</b> (less than 0.01%): Furunculosis, telangiectasia</p><p><b>Frequency not reported</b>: Exfoliative dermatitis, skin necrosis, skin ulceration, folliculitis, hidradenitis, allergic vasculitis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Inflammation and ulceration of the vagina</p><p><b>Very rare</b> (less than 0.01%): Loss of libido (males and females), impotence, impaired menstruation, vaginal discharge, infertility, abortion, fetal death, fetal defects, gynecomastia, defective oogenesis or spermatogenesis, transient oligospermia, vaginal bleeding<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Anorexia, nausea, vomiting, abdominal pain, inflammation, ulcerations of the mucous membrane of mouth and throat (especially during the first 24 to 48 hours after administration), stomatitis, dyspepsia, dehydration</p><p><b>Common</b> (1% to 10%): Diarrhea (especially during the first 24 to 48 hours after administration)</p><p><b>Uncommon</b> (0.1% to 1%): GI bleeding and ulcers, pancreatitis</p><p><b>Rare</b> (0.01% to 0.1%): Gingivitis, enteritis, melena, malabsorption </p><p><b>Very rare</b> (less than 0.01%): Hematemesis, toxic megacolon</p><p><b>Frequency not reported</b>: Glossitis<sup>[Ref]</sup></p><h3>General</h3><p>Generally, the incidence and severity of acute side effects are related to dose and frequency of administration.  The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, abdominal distress, malaise, undue fatigue, chills and fever, dizziness, and decreased resistance to infection.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Dysuria</p><p><b>Rare</b> (0.01% to 0.1%): Oliguria, anuria, azotemia</p><p><b>Very rare</b> (less than 0.01%): Proteinuria</p><p><b>Frequency not reported</b>: Cystitis, hematuria<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Leukocytopenia, thrombocytopenia, anemia</p><p><b>Uncommon</b> (0.1% to 1%): Pancytopenia, agranulocytosis, hematopoietic disorders</p><p><b>Rare</b> (0.01% to 0.1%): Megaloblastic anemia </p><p><b>Very rare</b> (less than 0.01%): Severe bone marrow depression, aplastic anemia, lymphadenopathy, lymphoproliferative disorders (partly reversible), eosinophilia, neutropenia </p><p><b>Frequency not reported</b>: Hemorrhage, hematoma, myelosuppression<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increase in liver related enzymes (ALAT, ASAT, alkaline phosphatase, bilirubin, and LDH levels) is commonly reported but usually resolves within one month after cessation of therapy</p><p><b>Uncommon</b> (0.1% to 1%): Development of liver fattening, fibrosis and cirrhosis (occurs frequently despite regularly monitored, normal values of liver enzymes), drop of serum albumin</p><p><b>Rare</b> (0.01% to 0.1%): Acute hepatitis, hepatotoxicity </p><p><b>Very rare</b> (less than 0.01%): Reactivation of chronic hepatitis, acute liver degeneration, liver insufficiency, liver failure, liver atrophy, necrosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic vasculitis, severe allergic reactions progressing to anaphylactic shock<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Disseminated herpes zoster, pneumocystis carinii pneumonia</p><p><b>Very rare</b> (less than 0.01%): Immunosuppression, hypogammaglobulinemia, sepsis, opportunistic infections (may be fatal in some cases), infections caused by the cytomegalic virus, acute paronychia</p><p><b>Frequency not reported</b>: Nocardiosis, cryptococcus mycosis, disseminated herpes simplex, listeria meningitis, mycobacterium avium, intracellular pneumonia, systemic fungal infections (e.g., cryptococcosis, nocardiosis, aspergillosis, histoplasmosis), sepsis, decreased resistance to infection, pneumocystis jiroveci, pneumonia (most common infection), respiratory tract infection, cutaneous bacterial infections, pneumonia, reactivation of hepatitis B infection, worsening of hepatitis C infection<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Osteoporosis, arthralgia, myalgia</p><p><b>Rare</b> (0.01% to 0.1%): Stress fracture, nodulosis </p><p><b>Very rare</b> (less than 0.01%): Pain, muscular asthenia or paresthesia of the extremities</p><p><b>Frequency not reported</b>: Osteoporosis, osteonecrosis (aseptic necrosis of the femoral head), soft tissue necrosis, abnormal tissue cell changes, arthralgia/myalgia, back pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, drowsiness</p><p><b>Uncommon</b> (0.1% to 1%): Vertigo, confusion, seizures, convulsion, encephalopathy</p><p><b>Very rare</b> (less than 0.01%): Paresis, effect on speech including dysarthria and aphasia, myelopathy, changes in sense of taste (metallic taste), meningism, acute aseptic meningitis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (0.01% to 0.1%): Severely impaired vision, visual disturbances, blurred vision </p><p><b>Very rare</b> (less than 0.01%): Conjunctivitis, retinopathy, transient blindness/loss of vision, periorbital edema, blepharitis, epiphora, photophobia, eye discomfort<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Lymphomas and leukemias have been associated with this drug<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very rare</b> (less than 0.01%): Fever, impaired wound healing</p><p><b>Frequency not reported</b>: Fetal death, fetal damage, abortion, tinnitus, chills, malaise, fatigue<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Inflammation and ulceration of the urinary bladder (possibly with hematuria)</p><p><b>Rare</b> (0.01% to 0.1%): Renal failure, elevated serum creatinine and urea level </p><p><b>Frequency not reported</b>: Renal insufficiency (usually with high doses), severe nephropathy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary complications due to interstitial alveolitis pneumonitis (e.g., general illness, dry/nonproductive cough, shortness of breath progressing to rest dyspnea, chest pain, fever)</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary fibrosis</p><p><b>Rare</b> (0.01% to 0.1%): Pharyngitis, apnea, bronchial asthma </p><p><b>Very rare</b> (less than 0.01%): Pneumocystis carinii pneumonia, chronic obstructive pulmonary disease, pleural effusion</p><p><b>Frequency not reported</b>: Acute pulmonary edema, pleurisy, hypoxia, respiratory failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Rare</b> (0.01% to 0.1%): Diabetes mellitus, hyperuricemia </p><p><b>Frequency not reported</b>: Metabolic disorder, tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (0.01% to 0.1%): Mood alterations </p><p><b>Very rare</b> (less than 0.01%): Insomnia, cognitive dysfunction</p><p><b>Frequency not reported</b>: Psychosis, depression, confusion, irritability<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Methotrexate Sodium (methotrexate)." Teva Pharmaceuticals (formerly IVAX), Miami, FL. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Does it cause weight gain?</li>
<li>How long does it take to work?</li>
<li>Why should I take folic acid with methotrexate?</li>
<li>How long does methotrexate stay in your system?</li>
<li>What are the different brands of methotrexate?</li>
</ul><h2>More about Methotrexate LPF Sodium (methotrexate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: antimetabolites</li>
<li>FDA Alerts (5)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
<li>Acute Lymphocytic Leukemia</li>
<li>Breast Cancer</li>
<li>Choriocarcinoma</li>
<li data-more-config-id="list-data-resources-conditions">... +17 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>